Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.
Apolipoprotein mimetic peptides dramatically reduce atherosclerosis in animal models, and may be an excellent mode of therapy to treat a variety of vascular inflammatory conditions, including atherosclerosis. Studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis, including viral influenza, asthma, chronic rejection after heart transplantation, sickle cell disease, scleroderma, diabetes, cognitive dysfunction and renal inflammation, suggest that apolipoprotein mimetic peptides may have efficacy in a wide range of inflammatory conditions.
Van Lenten
Brian J
BJ
David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA. bvanlent@mednet.ucla.edu
Navab
Mohamad
M
Anantharamaiah
G M
GM
Buga
Georgette M
GM
Reddy
Srinivasa T
ST
Fogelman
Alan M
AM
D000755:Anemia, Sickle Cell / Q000188:drug therapy; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D050197:Atherosclerosis / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy; D006084:Graft Rejection / Q000188:drug therapy; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D009393:Nephritis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D016632:Apolipoprotein A-I